Jane Chung - 09 Aug 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
Chief Executive Officer, Director
Signature
/s/ David Pauling as attorney-in-fact for Jane Chung
Issuer symbol
STRO
Transactions as of
09 Aug 2025
Net transactions value
-$5,366
Form type
4
Filing time
26 Aug 2025, 21:20:43 UTC
Previous filing
08 Apr 2025
Next filing
16 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chung Jane Chief Executive Officer, Director C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO /s/ David Pauling as attorney-in-fact for Jane Chung 26 Aug 2025 0001872398

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +18,750 +19% $0.000000 117,058 09 Aug 2025 Direct
transaction STRO Common Stock Tax liability $5,366 -6,708 -5.7% $0.8000 110,350 09 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -18,750 -100% $0.000000 0 09 Aug 2025 Common Stock 18,750 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3 The RSUs vested or vest as to 1/4th of the total award annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.